Jun 11 |
Tonix Pharmaceuticals announces proposed public offering
|
Jun 11 |
Tonix Pharmaceuticals Announces Proposed Public Offering
|
Jun 6 |
Tonix Pharmaceuticals announces 1-for-32 reverse stock split
|
Jun 6 |
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
|
Jun 5 |
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
|
Jun 3 |
Tonix Pharmaceuticals Presented New Data on Tonmyaâ„¢ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting
|
May 30 |
Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting
|
May 29 |
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
|
May 28 |
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
|
May 22 |
Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
|